INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. METHODS: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. RESULTS: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. CONCLUSIONS: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).

Centre for Experimental Pathogen Host Research University College Dublin School of Medicine National University of Ireland Dublin Ireland

Centro Hospitalar Universitário do Porto Porto Portugal

Centro Nacional de Microbiología Instituto de Salud Carlos 3 Madrid Spain

Collaborative Center for Clinical Epidemiology and Outcomes Research Athens Greece

Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden Division of Infectious Diseases Department of Medicine Solna Karolinska Institutet Stockholm Sweden

European University of Cyprus Nicosia Cyprus

European Vaccine Initiative Heidelberg Germany

Haceteppe University Ankara Turkey

Hospital La Paz Institute for Health Research Madrid Spain; Servicio Madrileño de Salud Madrid Spain

Influenza Centre Department of Clinical Science University of Bergen Bergen Norway

Institut National de la Santé et de la Recherche Médicale ANRS Maladies Infectieuses Émergentes Paris France; Université Paris Cité Assistance Publique Hopitaux de Paris Paris France

Institute of Clinical Medicine Medical Faculty Vilnius University|Institute of Clinical Medicine Medical Faculty Vilnius University; Vilnius University Hospital Santaros klinikos Vilnius University Medical Faculty Vilnius Lithuania

Masaryk University Brno Czech Republic University Hospital Brno Brno Czech Republic CZECRIN Brno Czech Republic

Medical University of Vienna Vienna Austria

Ministry of Health of Israel Jerusalem Israel

National Koranyi Institute for Pulmonology Budapest Hungary

Universiteit Antwerpen Faculty of Medicine and Health Science VAXINFECTIO Centre of Evaluation of Vaccination Antwerp Belgium

University of Cologne Faculty of Medicine and University Hospital Cologne Translational Research Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases Cologne Germany

University of Cologne Faculty of Medicine and University Hospital Cologne Translational Research Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases Partner Site Bonn Cologne Cologne Germany

University of Verona Infectious Diseases Department of Diagnostic and Public Health Verona Italy

Zobrazit více v PubMed

World Health Organization. Pneumonia of unknown cause www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (Last accessed December 1, 2021).

Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368 PubMed

European Centre for Disease Prevention and Control. Why is pandemic preparedness planning important? www.ecdc.europa.eu/en/seasonal-influenza/preparedness/why-pandemic-preparedness (Last accessed December 3, 2021).

Nature. Has COVID taught us anything about pandemic preparedness? www.nature.com/articles/d41586-021-02217-y (Last accessed November 29, 2021). PubMed

Shapiro LI, Kajita GR, Arnsten JH, Tomer Y. Toward better preparedness for the next pandemic. J Clin Invest 2020;130:4543-45. PubMed PMC

Baker R.E., Mahmud A.S., Miller I.F., Rajeev M., Rasambainarivo F., Rice B.L., et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20(4):193–205. PubMed PMC

Leroy O., Geels M., Korejwo J., Dodet B., Imbault N., Jungbluth S. Roadmap for the establishment of a European vaccine R&D infrastructure. Vaccine. 2014;32:7021–7024. PubMed

E. U-Response investigators group, Diallo A, Troseid M, Simensen VC, Boston A, Demotes J, et al. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect 2021; PubMed PMC

Giannuzzi V., Felisi M., Bonifazi D., Devlieger H., Papanikolaou G., Ragab L., et al. Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project. BMC Med Ethics. 2021;22(1) doi: 10.1186/s12910-021-00618-2. PubMed DOI PMC

Magnin A., Iversen V.C., Calvo G., Čečetková B., Dale O., Demlová R., et al. European survey on national harmonization in clinical research. Learn Health Syst. 2021;5(2) doi: 10.1002/lrh2.v5.210.1002/lrh2.10220. PubMed DOI PMC

Lythgoe M.P., Middleton P. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. JAMA Netw Open. 2021;4(6):e2114531. doi: 10.1001/jamanetworkopen.2021.14531. PubMed DOI PMC

Lankinen K.S., Pastila S., Kilpi T., Nohynek H., Makela P.H., Olin P. Vaccinovigilance in Europe–need for timeliness, standardization and resources. Bull World Health Organ. 2004;82:828–835. PubMed PMC

Centers for Disease Control and Prevention. Vaccine Testing and the Approval Process www.cdc.gov/vaccines/basics/test-approve.html (Last accessed November 30, 2021).

European Vaccination Information Portal. Approval of vaccines in the European Union www.vaccination-info.eu/en/vaccine-facts/approval-vaccines-european-union (Last accessed December 2, 2021).

ECRIN - European Clinical Research Infrastructure Network www.ecrin.org (Last accessed December 2, 2021).

VACCELERATE-EUVAP European Vaccine Trial Accelerator Platform www.euvap.eu (Last accessed December 1, 2021).

COMBACTE - Combatting antimicrobial resistance www.combacte.com/ (Last accessed December 2, 2021).

COVIREIVAC www.covireivac.fr (Last accessed December 1, 2021).

Chaudhari N., Ravi R., Gogtay NithyaJ, Thatte UrmilaM. Recruitment and retention of the participants in clinical trials: Challenges and solutions. Perspect Clin Res. 2020;11(2):64. doi: 10.4103/picr.PICR_206_19. PubMed DOI PMC

VACCELERATE-European Corona Vaccine Trial Accelerator Platform www.vaccelerate.eu (Last accessed December 1, 2021).

European Commission. EU Health Emergency Preparedness and Response Authority (HERA) Incubator www.ec.europa.eu/commission/presscorner/detail/en/ip_21_4672 (Last accessed November 24, 2021).

EU General Data Protection Regulation (GDPR) https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:02016R0679-20160504&from=EN (Last accessed December 15, 2021).

EUPATI-European Patients’ Academy on Therapeutic Innovation www.eupati.eu (Last accessed December 2, 2021).

Think Young www.thinkyoung.eu (Last accessed November 30, 2021).

Vogazianos P., Argyropoulos C.D., Haralambous C., Mikellidou C.V., Boustras G., Andreou M., et al. Impact assessment of COVID-19 non-pharmaceutical interventions in long term care facilities in Cyprus: Safety improvement strategy. Saf Sci. 2021;143:105415. doi: 10.1016/j.ssci.2021.105415. PubMed DOI PMC

EPF - European Patients' Forum www.eu-patient.eu (Last accessed November 30, 2021).

The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit